1. FRI0099 Liver enzyme abnormalities after tofacitinib treatment in patients with hepatic steatosis from the rheumatoid arthritis, psoriatic arthritis and psoriasis clinical programmes. (12th June 2018) Authors: Soriano, E.R.; Madariaga, H.; Castañeda, O.; Citera, G.; Schneeberger, E.E.; Cardiel, M.H.; Hendrikx, T.; Graham, D.; Shi, H.; Ponce de Leon, D. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 593 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. FRI0115 FILGOTINIB PROVIDED RAPID AND SUSTAINED IMPROVEMENTS IN FUNCTIONAL STATUS, PAIN, AND HEALTH-RELATED QUALITY OF LIFE, AND REDUCED FATIGUE OVER TIME IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO ARE METHOTREXATE-NAÏVE: RESULTS FROM THE FINCH 3 STUDY. (2nd June 2020) Authors: Alten, R.; Rigby, W.; Pechonkina, A.; Yin, Z.; Hasegawa, K.; Hendrikx, T.; Atsumi, T.; Westhovens, R. Journal: Annals of the rheumatic diseases Issue: Volume 79(2020)Supplement 1 Page Start: 638 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Haematopoetic TREM2 deficiency modulates atherosclerosis and lipid metabolism. (December 2020) Authors: Porsch, F.; Kiss, M.G.; Goederle, L.; Hendrikx, T.; Hladik, A.; Knapp, S.; Binder, C.J. Journal: Atherosclerosis Issue: Volume 315(2020) Page Start: e58 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Hematopoietic complement factor H deficiency reduces atherosclerosis in LDLR-deficient mice. (August 2018) Authors: Kiss, M.; Tsiantoulas, D.; Papac-Milicevic, N.; Göderle, L.; Ozsvar-Kozma, M.; Hendrikx, T.; Bartolini Gritti, B.; Porsch, F.; Swirski, F.K.; Binder, C.J. Journal: Atherosclerosis Issue: Volume 275(2018) Page Start: e13 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Indoles: metabolites produced by intestinal bacteria capable of controlling liver disease manifestation. (14th March 2019) Authors: Hendrikx, T.; Schnabl, B. Journal: Journal of internal medicine Issue: Volume 286:Number 1(2019) Page Start: 32 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Lysosomal cholesterol accumulation: driver on the road to inflammation during atherosclerosis and non‐alcoholic steatohepatitis. Issue 5 (16th March 2014) Authors: Hendrikx, T.; Walenbergh, S. M. A.; Hofker, M. H.; Shiri‐Sverdlov, R. Journal: Obesity reviews Issue: Volume 15:Issue 5(2014) Page Start: 424 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Non-alcoholic steatohepatitis is reflected by levels of systemic soluble TREM2 and limited by the recruitment of TREM2-positive macrophages to areas of lipid-induced tissue damage. (August 2022) Authors: Porsch, F.; Kiss, M.G.; Rajčić, D.; Papac-Milicevic, N.; Goederle, L.; Hladik, A.; Derdak, S.; Shaw, L.E.; Heintz, L.; Paternostro, R.; Farlik, M.; Knapp, S.; Krawczyk, M.; Trauner, M.; Bilban, M.; Wolf, D.; Binder, C.J.; Hendrikx, T. Journal: Atherosclerosis Issue: Volume 355(2022) Page Start: 18 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. OP0002 Tofacitinib in Patients with Ankylosing Spondylitis: A Phase 2, 16-Week, Randomised, Placebo-Controlled, Dose-Ranging Study. (15th July 2016) Authors: van der Heijde, D.; Deodhar, A.; Wei, J.C.; Drescher, E.; Fleishaker, D.; Hendrikx, T.; Li, D.; Menon, S.; Kanik, K. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 52 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. SAT0243 Incidence of thromboembolic events in the tofacitinib rheumatoid arthritis, psoriasis, psoriatic arthritis and ulcerative colitis development programmes. (12th June 2018) Authors: Mease, P.J.; Kremer, J.; Cohen, S.; Curtis, J.R.; Charles-Schoeman, C.; Loftus, E.V.; Greenberg, J.; Palmetto, N.; Kanik, K. S.; Graham, D.; Wang, C.; Biswas, P.; Chan, G.; DeMasi, R.; Valdez, H.; Hendrikx, T.; Jones, T. V. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 983 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. SAT0293 Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study. (12th June 2018) Authors: Nash, P.; Coates, L.C.; Kivitz, A.J.; Mease, P.J.; Gladman, D.D.; Covarrubias-Cobos, J.A.; Fleishaker, D.; Wang, C.; Kudlacz, E.; Menon, S.; Fallon, L.; Hendrikx, T.; Kanik, K.S. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 1010 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗